Accuracy of Using 2D Transesophageal Echocardiography Compared to Balloon Sizing in Determining Valve Size During Transcatheter Aortic Valve Implantation

NCT04242225 | Unknown DMC

• 1 other identifier: AssiutUni
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The method of transcatheter aortic valve implantation (TAVI) introduced in 2002 by Alain Cribier et al. has offered new prospects for patients with severe aortic stenosis and multiple comorbidities, who are at high operative risk(1). The PARTNER series of randomized controlled trials has firmly established the role of TAVI with the balloon-expandable Edwards Sapien valve in patients with severe symptomatic aortic stenosis (AS) at prohibitive risk of surgery (PARTNER IA), high risk for surgery (PARTNER IB), and intermediate risk for surgery (PARTNER 2).(2) Also PARTNER 3 and Evolut Low Risk trial strongly suggest that TAVI is not only a suitable alternative and may be superior to surgical aortic valve replacement ( SAVR) in low-risk patients.(2) The accurate determination of the size of the implant is dependent on pre-procedural imaging. Annular measurements are important in the TAVI as inaccurate estimation can lead to complications e.g paravalvular leakage .(3) Transthoracic echocardiography (TTE), transoesophageal echocardiography (TOE), multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) have been extensively studied with respect to pre-procedural aortic annular sizing.(3). However, even with some of the evidence returning a discrepancy in annular measurements between techniques, the literature to date does not clarify whether TOE undersizes inappropriately or appropriately with respect to MDCT.(3) In a recent study, 29.5% of patients would have been deemed ineligible for TAVI because of overestimation of annular measurements by MDCT, a figure reduced to 1.3% with the use of TOE (4) In a recent small retrospective study, TOE, MDCT and MRI all performed comparatively well with device sizing. (5) Balloon aortic valvuloplasty (BAV) dilatation before TAVI is considered a mandatory procedural step in the early years of TAVR. BAV is used to confirm annular sizing and to enhance trans-catheter heart valve (THV) deliverability.(6) However till now there is no comparison of annular measurement by 2D transesophgeal echocardiography with balloon sizing.

Conditions

Aortic Stenosis, Calcific

Outcome Measures

Primary Outcomes (1)

• accuracy of 2D transesophgeal echocardiography compared to balloon sizining in determining size of valve during TAVI

  accuracy of 2D transesophgeal echocardiography compared to balloon sizining in determining size of valve during TAVI

  6 months

Secondary Outcomes (1)

• in hospital outcomes of this approach using 2D TEE and balloon sizing only during TAVI

  6 months

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients with severe aortic stenosis presented for TAVI

You may qualify if:

• Patients must have severe degenerative high flow AS (echocardiographic criteria: aortic valve (AV) effective orifice area (EOA) of \< 1 cm2, mean AV gradient of \> 40 mmHg, or AV peak systolic velocity of \> 4.0 m/s) in presence of normal ejection fraction (EF).
• Patients must be symptomatic from the AS (dyspnea in NYHA-class II or greater, angina pectoris, or syncope), or asymptomatic but with decreased left ventricular ejection fraction, positive stress test , Pulmonary hypertension (systolic pulmonary artery pressure \>60 mmHg).
• Symptomatic patients with severe low-flow, low-gradient (\<40 mmHg) aortic stenosis with reduced ejection fraction and evidence of flow (contractile) reserve.
• Patients surviveal time more than one year . 4- Patients have contraindications for open chest surgery, such as :
• Presence of comorbidities not adequately reflected by risk scores.
• Procelain aorta
• Squelae of chest radiation.
• Severe chest deformation or scoliosis.
• Previous cardiac surgery

You may not qualify if:

• Evidence of an acute myocardial infarction 30 days before the intended treatment.
• Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified.
• Mixed aortic stenosis and aortic regurgitation with predominant aortic regurgitation \> 3+).
• Hemodynamic or respiratory instability within 30 days of screening evaluation.
• Need for emergency surgery for any reason.
• Hypertrophic cardiomyopathy with or without obstruction.
• Severe left ventricular dysfunction with LVEF \<20%.
• Severe pulmonary hypertension and RV dysfunction.
• Echocardiographic evidence of intracardiac mass, thrombus or vegetation. . 10-A known contraindication to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
• MRI confirmed stroke or transient ischemic attack within 6 months (180 days) of the procedure.
• Renal insufficiency (creatinine \>3mg) and / or end stage renal insufficiency requiring chronic dialysis at the time of screening.
• Estimated life expectancy\<12 month.
• Severe incapacitating dementia 15-Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5 cm or greater; marked tortuosity (hyperacute bend), aortic arch atheroma \[especially if thick (\>5 mm), protruding or ulcerated\] or narrowing of the abdominal or thoracic aorta, severe tortuosity of the thoracic aorta.
• Also a minimum iliac or femoral artery diameter of less than 6 mm may be deemed unsuitable for femoral approach.
• Severe mitral regurgitation. 17-Annulus size out of range of available prosthese (\<18mm and \>29mm). 18-Untreated coronary artery disease requiring revascularization. 19- Elevated risk of coronary ostium obstruction (asymmetric valve calcification, short distance between annulus and coronary ostium less than 10mm.

Sponsors & Collaborators

• Assiut University: lead
• Duisburg Heart center ,Dusseldorf University ,Germany: collaborator

Study Sites (1)

AssiutU

Asyut, 17717, Egypt

RECRUITING

MeSH Terms

Conditions

Aortic Valve, Calcification of

Study Officials

• Marwan Sa Mahmoud, Master

  Assiut University

  PRINCIPAL INVESTIGATOR

• Marwan Sa Mahmoud, Master

  HZD

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marwan Sa Mahmoud, MD

CONTACT

01090686492; Marwancardio@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 7 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assiut university Heart Hospital

Study Record Dates

• First Submitted: January 23, 2020
• First Posted: January 27, 2020
• Study Start: January 1, 2020
• Primary Completion: September 1, 2020
• Study Completion: October 1, 2020
• Last Updated: September 1, 2020

Record last verified: 2020-08

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)